Arcadia Biosciences EBIT

The latest EBIT for RKDA is $4M as of June 2026. That compares with $-9.5M in the prior-year period — up 141.9% year over year. That is below the Materials sector average of $30B. Investors often review this figure alongside Arcadia Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RKDA's EBIT moved from $-9.5M to $4M — a 141.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Arcadia Biosciences's operating scale or balance-sheet position.

Against Materials companies, RKDA currently prints $4M for EBIT, while the sector average sits near $30B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Arcadia Biosciences's growth, margins, and balance sheet.

A EBIT figure of $4M for RKDA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Materials average is about $30B. Explore the charts below for those layers of context.

After noting RKDA's EBIT ($4M), review year-over-year change from $-9.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.